Ortec seeks HDE (Humanitarian Device Exemption) for skin product:
This article was originally published in Clinica
Ortec International is seeking US FDA approval to market its Composite Cultured Skin (CCS) product as a treatment for four critical skin conditions under a Humanitarian Device Exemption (HDE). If the application is approved, the product, composed of a bioengineered bovine collagen matrix seeded with dermal and epidermal cells, will be used to treat patients suffering from epidermolysis bullosa, Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme. The New York-based company expects to receive notification from the FDA within 75 days. An HDE allows companies to market devices for treating conditions that affect less than 4,000 in the US.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.